Output details
15 - General Engineering
King's College London
Article title
MEK1/2 Inhibition Decreases Lactate in BRAF-Driven Human Cancer Cells
Type
D - Journal article
Title of journal
Cancer Research
Article number
-
Volume number
73
Issue number
13
First page of article
4039
ISSN of journal
0008-5472
Year of publication
2013
URL
-
Number of additional authors
6
Additional information
In this paper we demonstrated for the first time that human cancer cells containing the highly activating V600D or V600E BRAF mutation, lead to upregulated MEK1/2 signalling, and reduced extracellular lactate levels following MEK1/2 inhibition, as measured by magnetic resonance spectroscopy. BRAF-MEK1/2-ERK1/2 signalling is deregulated in many human cancers and constitutes a focus for contemporary anticancer drug development. The paper informs on an important aspect of cancer cell metabolism and clarified the potential mechanisms of action of new drugs, such as PLX4032, being trialed in V600E BRAF melanoma. Eykyn devised and performed the MR spectroscopic studies.
Interdisciplinary
-
Cross-referral requested
-
Research group
None
Proposed double-weighted
No
Double-weighted statement
-
Reserve for a double-weighted output
No
Non-English
No
English abstract
-
